Revolutionizing in vivo gene delivery to usher in a new era of genetic medicines.
A biotechnology company.
Developing novel antibody drug conjugates (ADCs) against novel targets in multiple solid tumors.
Pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics.
On a mission to revolutionize treatment options for patients with severe liver disease.
Focused on innovating genetic analysis tools for the research and diagnostics market.
Targeting inflammation in cardiovascular and renal disease.
The future of microbiome therapeutics.
Leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases.